Madeleine Carens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madeleine Carens has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Brian Keith
University of Pennsylvania 1 Abramson Family Cancer Research Institute, Perelman School of Medicine Philadelphia, Pennsylvania
24 shared publications - M. Celeste Simon
Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
24 shared publications - Nathan J. Coffey
University of Pennsylvania 1 Abramson Family Cancer Research Institute, Perelman School of Medicine Philadelphia, Pennsylvania
24 shared publications - Nicolas Skuli
University of Pennsylvania 1 Abramson Family Cancer Research Institute, Perelman School of Medicine Philadelphia, Pennsylvania
24 shared publications - Romain Riscal
Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Sara Demczyszyn
University of Pennsylvania 1 Abramson Family Cancer Research Institute, Perelman School of Medicine Philadelphia, Pennsylvania
24 shared publications
Latest Publications
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF22
Targeting Branched-Chain Amino Acid Transamination Sensitizes Clear-Cell Renal Cell Carcinoma to Glutaminase Inhibition
Metabolic reprogramming is a well-described hallmark of clear-cell renal cell carcinoma (ccRCC). Gene copy-number variation and altered gene expression data suggest that enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate (GLU)-derived glutathione (GSH) and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase (GLS) inhibitor CB-839 by providing GSH independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839–mediated GLS inhibition by decreasing GSH biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical GLU and GSH levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials, and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to GLS inhibition. Significance: Branched-chain amino acid transamination maintains essential glutamate and glutathione levels in glutamine-deprived clear cell renal cell carcinoma and can be targeted to sensitize tumors to glutaminase inhibition by impairing redox homeostasis.
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF22
Targeting Branched-Chain Amino Acid Transamination Sensitizes Clear-Cell Renal Cell Carcinoma to Glutaminase Inhibition
Metabolic reprogramming is a well-described hallmark of clear-cell renal cell carcinoma (ccRCC). Gene copy-number variation and altered gene expression data suggest that enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate (GLU)-derived glutathione (GSH) and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase (GLS) inhibitor CB-839 by providing GSH independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839–mediated GLS inhibition by decreasing GSH biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical GLU and GSH levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials, and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to GLS inhibition. Significance: Branched-chain amino acid transamination maintains essential glutamate and glutathione levels in glutamine-deprived clear cell renal cell carcinoma and can be targeted to sensitize tumors to glutaminase inhibition by impairing redox homeostasis.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S8 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S8 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S8 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S4 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S4 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S2 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S2 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S1 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S1 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S5 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S9 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S9 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S9 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S3 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S3 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S7 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma
Figure S7 from Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma